Hypermarcas traded at 20.98 this Friday June 5th, decreasing 0.33 or 1.55 percent since the previous trading session. Looking back, over the last four weeks, Hypermarcas lost 10.61 percent. Over the last 12 months, its price fell by 19.28 percent. Looking ahead, we forecast Hypermarcas to be priced at 21.30 by the end of this quarter and at 19.58 in one year, according to Trading Economics global macro models projections and analysts expectations.
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.